Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. Show more
Location: 1901 West 47th Place, Kansas City, KS, 66205, United States | Website: https://www.cingulate.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
21.47M
52 Wk Range
$3.02 - $6.01
Previous Close
$3.83
Open
$3.75
Volume
60,136
Day Range
$3.70 - $3.85
Enterprise Value
19.15M
Cash
8.90M
Avg Qtr Burn
-4.342M
Insider Ownership
1.81%
Institutional Own.
5.27%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
CTx-1301 (dexmethylphenidate) Details Attention deficit hyperactivity disorder | NDA Acceptance for review | |
CTx-1302 (dextroamphetamine) Details Attention deficit hyperactivity disorder | Phase 1/2 Initiation | |
CTx-2103 (buspirone) Details Anxiety Disorders | IND Submission |